FinancialContent

Articles published by Incyte

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
From Incyte
Via Business Wire
Tickers INCY
News headline image
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
News headline image
Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
News headline image
Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Names New Member to Its Board of Directors
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
From Incyte
Via Business Wire
Tickers INCY
News headline image
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
From Incyte
Via Business Wire
Tickers INCY
< Previous 1 2 3 4 5 6 7 Next >